|
|
Article: Genentech and IDEC Pharmaceuticals to Collaborate on Anti-CD20 Monoclonal Antibody for B-Cell Lymphomas.
- Article from:
- Business Wire
- Article date:
- March 16, 1995
CopyrightCOPYRIGHT 1995 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SOUTH SAN FRANCISCO and SAN DIEGO, Calif.--(BUSINESS WIRE)-- March 16, 1995--Genentech, Inc. (NYSE:GNE) and IDEC Pharmaceuticals Corporation (NASDAQ:IDPH) today announced that the two companies will collaborate on the clinical development and commercialization of IDEC's anti-CD20 monoclonal antibody, IDEC-C2B8, for the treatment of non-Hodgkin's B-cell lymphomas. IDEC-C2B8 is expected to enter Phase III clinical trials by mid-1995. In addition, Genentech has the option to extend its collaboration with IDEC to include two radioconjugates, IDEC-Y2B8 and IDEC-In2B8, also for the treatment of B-cell lymphomas.
Under the terms of the agreement, Genentech will provide $9 ...